Psoriasis vulgaris is the most common form of psoriasis. It causes patches of scaly, inflamed skin and can occur across the body. Vulgaris is Latin for ‘common’, so it means a common form of psoriasis ...

The risk for malignancy among patients who were treated with biologic therapies was compared with the risk among patients treated with topical therapies.

A low-fat diet has likewise received favorable recognition in the treatment of psoriasis. Grütz and Bürger, 12 the originators of this therapy, concluded that psoriasis was a "lipoidosis" and that a ...

In the VALOR trial, brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared ...

Psoriasis is a common immune disorder whose major manifestation is in the skin. It most frequently begins in young adults, and is a lifelong condition. The most common form of psoriasis — psoriasis ...

Psoriasis and psoriatic arthritis show genetic predispositions, but genetic influences on clinical characteristics are poorly understood. In a study conducted in Japan, patients with psoriasis and a ...

Ten-year mean costs associated with psoriasis-related health care visits were 10 times higher for patients with generalized pustular psoriasis (GPP). Patients with generalized pustular psoriasis (GPP) ...

Have there been any reports in the literature linking improvement of psoriasis vulgaris with initiation of long-term, low-dose aspirin therapy, even when usual therapy has failed? I have seen marked ...

Purpose To investigate the validity of direct and indirect health state utility (HSU) and subjective well-being measures in psoriasis vulgaris patients. Methods A convenience sampling framework was ...

To address this intriguing question, Egeberg and colleagues used the Danish National Patient Register to gather data from Danish adults (age >18 years) over a 14-year period (n = 5,379,859). This deep ...

Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...